Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD70-CAR-T in Advanced/Metastatic Renal Cell Carcinoma
NCT06586658Phase 1Suspended
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Sep 2024
- Primary completion
- Jul 2027
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CTX130 in renal cell carcinoma (RCC), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Dose-limiting toxicity at 28 days, Incidence and severity of adverse events at 1 year and 1 more. Started Sep 2024; status: suspended.
02
Drugs
CTX130
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06586658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586658.